Fidelis Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Fidelis Capital Partners's VRTX Position: Q2 2026 in Review
Fidelis Capital Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 1.5% in Q2 2026, selling an estimated $14.2K and leaving 2,123 shares worth $1.05M. The position accounts for 0.06% of the portfolio, ranked #222.
Fidelis Capital Partners first reported a position in VRTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.77M in Q1 2025. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Fidelis Capital Partners held 2,123 shares of Vertex Pharmaceuticals worth $1.05M as of Q2 2026.
- Fidelis Capital Partners sold 32 Vertex Pharmaceuticals shares in Q2 2026, an estimated $14.2K.
- Vertex Pharmaceuticals made up 0.06% of Fidelis Capital Partners's portfolio in Q2 2026, its #222 holding.
- Fidelis Capital Partners first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
- Fidelis Capital Partners's Vertex Pharmaceuticals position peaked at $2.77M in Q1 2025.
- 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Fidelis Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.